Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.

Lindsay E CleggYankang JingRobert C PenlandDavid W BoultonAdrian F HernandezRury R HolmanJiten Vora

Published in: Diabetes, obesity & metabolism (2021)

This analysis of participants with CKD stages 3 to 4 from two cardiovascular outcomes trials supports the cardiorenal safety of metformin, but does not suggest a consistent benefit on MACE, ACM, or eGFR slope across this population.

Keyphrases

chronic kidney disease
end stage renal disease
small cell lung cancer
epidermal growth factor receptor
high intensity
drug induced